{
  "id": "54e0d1491388e8454a000014",
  "type": "factoid",
  "question": "Which enzyme is targeted by Evolocumab?",
  "ideal_answer": "Evolocumab (AMG145) is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) that demonstrated marked reductions in plasma low-density lipoprotein cholesterol concentrations in statin-intolerant patients.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24691094",
    "http://www.ncbi.nlm.nih.gov/pubmed/25410046",
    "http://www.ncbi.nlm.nih.gov/pubmed/25052769",
    "http://www.ncbi.nlm.nih.gov/pubmed/24661068",
    "http://www.ncbi.nlm.nih.gov/pubmed/24477778",
    "http://www.ncbi.nlm.nih.gov/pubmed/25079474",
    "http://www.ncbi.nlm.nih.gov/pubmed/24662398",
    "http://www.ncbi.nlm.nih.gov/pubmed/25470376",
    "http://www.ncbi.nlm.nih.gov/pubmed/24694531",
    "http://www.ncbi.nlm.nih.gov/pubmed/24961142",
    "http://www.ncbi.nlm.nih.gov/pubmed/24481874",
    "http://www.ncbi.nlm.nih.gov/pubmed/24373748",
    "http://www.ncbi.nlm.nih.gov/pubmed/25282520",
    "http://www.ncbi.nlm.nih.gov/pubmed/24953393",
    "http://www.ncbi.nlm.nih.gov/pubmed/24953396",
    "http://www.ncbi.nlm.nih.gov/pubmed/25002170",
    "http://www.ncbi.nlm.nih.gov/pubmed/24859266",
    "http://www.ncbi.nlm.nih.gov/pubmed/24678979",
    "http://www.ncbi.nlm.nih.gov/pubmed/25282519",
    "http://www.ncbi.nlm.nih.gov/pubmed/24255061",
    "http://www.ncbi.nlm.nih.gov/pubmed/24509273",
    "http://www.ncbi.nlm.nih.gov/pubmed/24284914",
    "http://www.ncbi.nlm.nih.gov/pubmed/24598985",
    "http://www.ncbi.nlm.nih.gov/pubmed/24825642"
  ],
  "snippets": [
    {
      "text": "Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661068",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "AREAS COVERED: Evolocumab (AMG145) is a monoclonal antibody inhibiting the proprotein convertase subtilisin/kexin type 9 that binds to the liver LDL receptor and prevents it from normal recycling by targeting it for degradation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661068",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598985",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We report a pooled analysis from four phase 2 studies of evolocumab (AMG 145), a monoclonal antibody to PCSK9. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598985",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24509273",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "METHODS: A pooled analysis of data from 1,359 patients in 4 phase II trials assessed the effects of evolocumab, a fully human monoclonal antibody to PCSK9, on Lp(a), the relationship between Lp(a) and lowering of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B, and the influence of background statin therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24509273",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Inhibition of PCSK9 with evolocumab resulted in significant dose-related reductions in Lp(a). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24509273",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9, including evolocumab (previously AMG 145), dramatically lowered LDL-C in phase 2 clinical trials when administered alone or in combination with a statin. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24481874",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evolocumab (AMG 145) is a fully human monoclonal antibody that binds PCSK9, inhibiting its interaction with the LDL receptor to preserve LDL-receptor recycling and reduce LDL-C.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24477778",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Antibody therapeutics in Phase 3 studies are described, with an emphasis on those with study completion dates in 2014, including antibodies targeting interleukin-17a or the interleukin-17a receptor (secukinumab, ixekizumab, brodalumab), proprotein convertase subtilisin/kexin type 9 (alirocumab, evolocumab, bococizumab), and programmed death 1 receptor (lambrolizumab, nivolumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24284914",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Evolocumab (AMG 145), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein cholesterol (LDL-C) in phase 2 studies of 12 weeks' duration. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255061",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These compounds act either by reducing low-density lipoprotein (LDL) production by inhibiting apolipoprotein B synthesis with an antisense oligonucleotide (mipomersen) or by inhibiting microsomal triglyceride transfer protein (lomitapide), or by enhancing LDL catabolism via monoclonal antibody-mediated inhibition of the activity of proprotein convertase subtilisin/kexin 9 (PCSK9) (evolocumab). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25410046",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25282520",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Evolocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), reduced LDL cholesterol by 16% in a pilot study. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25282520",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25282519",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We investigated the effect of PCSK9 inhibition with evolocumab (AMG 145) on LDL cholesterol in patients with this disorder. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25282519",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Some of the anti-dyslipidemic drugs which work by PCSK9 inhibition include evolocumab, alirocumab and ALN-PCS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25079474",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We highlight the different steps of this adventure and review the published clinical trials especially those with the anti-PCSK9 antibodies evolocumab (AMG 145) and alirocumab (SAR236553/REGN727), which are in phase III trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052769",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Monoclonal antibodies against PCSK9 represent so far the most advanced approach in clinical development, with alirocumab, evolocumab and bococizumab under advanced clinical development. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25002170",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AREAS COVERED: Evolocumab and alirocumab are fully human monoclonal antibodies inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) that binds to hepatic LDL receptor and prevents it from normal recycling by targeting it for degradation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24961142",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase II (for evolocumab and alirocumab) and III (for evolocumab) trials show that PCSK9 inhibitors are equally well tolerated, with adverse events mainly limited to mild-to-moderate nasopharyngitis, injection-site pain, arthralgia and back pain. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24961142",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Four classes of newer lipid-lowering drugs offer promising advances in treating FH, namely the apolipoprotein-B synthesis inhibitors (mipomersen), the microsomal transfer protein inhibitors (lomitapide), the cholesterol ester transfer protein inhibitors (anacetrapib, evacetrapib) and the proprotein convertase subtilisin/kexin type 9 inhibitors (evolocumab, alirocumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24953396",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Monoclonal antibodies that inhibit proprotein convertase subtilisin/ kexin type 9 (PCSK9), which degrades the LDL receptor, like alirocumab and evolocumab, are in phase 3 trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24953393",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In support of the drug development program for Evolocumab, a fully human IgG\u2082 antibody that targets PCSK9, a quantitative ELISA to measure free PCSK9 in human serum was developed. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24859266",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "IMPORTANCE: In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24825642",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24694531",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Evolocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), demonstrated marked reductions in plasma low-density lipoprotein cholesterol (LDL-C) in a phase 2 study in statin-intolerant patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24694531",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24691094",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced LDL-C in phase II trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24691094",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24678979",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24662398",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "proprotein convertase subtilisin/kexin type 9"
}